Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning (Review)

Haruko Irie, Kouji Banno, Megumi Yanokura, Miho Iida, Masataka Adachi, Kanako Nakamura, Kiyoko Umene, Yuya Nogami, Kenta Masuda, Yusuke Kobayashi, Eiichiro Tominaga, Daisuke Aoki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Metformin is a first-line drug used for the treatment of type 2 diabetes. Recently, metformin has been reported to reduce the carcinogenic risk and inhibit tumor cell growth in glioma and breast cancer. The anticancer action of metformin involves the enhancement of phosphorylation of liver kinase B1, activation of adenosine monophosphate-activated protein kinase and inhibition of mammalian target of rapamycin, which reduces cell growth. Metformin is anticipated to exert antitumor effects in gynecological cancer, and its efficacy for the treatment of endometrial, breast and ovarian cancer has been suggested in preclinical studies and clinical trials. Although the effect of metformin on cervical cancer remains to be examined in clinical trials, its antitumor effects have been reported in preclinical studies. Thus, the use of metformin for the treatment of gynecological cancer may become a successful example of drug repositioning, following establishment of the drug's antitumor effects, risk evaluation, screening and validation of efficacy.

Original languageEnglish
Pages (from-to)1287-1293
Number of pages7
JournalOncology Letters
Volume11
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Drug Repositioning
Metformin
Neoplasms
Clinical Trials
Breast Neoplasms
Sirolimus
Adenosine Monophosphate
Endometrial Neoplasms
Growth
Glioma
Uterine Cervical Neoplasms
Antineoplastic Agents
Ovarian Neoplasms
Protein Kinases
Type 2 Diabetes Mellitus
Phosphotransferases
Phosphorylation
Liver
Pharmaceutical Preparations

Keywords

  • Breast cancer
  • Drug repositioning
  • Endometrial cancer
  • Metformin
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Metformin : A candidate for the treatment of gynecological tumors based on drug repositioning (Review). / Irie, Haruko; Banno, Kouji; Yanokura, Megumi; Iida, Miho; Adachi, Masataka; Nakamura, Kanako; Umene, Kiyoko; Nogami, Yuya; Masuda, Kenta; Kobayashi, Yusuke; Tominaga, Eiichiro; Aoki, Daisuke.

In: Oncology Letters, Vol. 11, No. 2, 01.02.2016, p. 1287-1293.

Research output: Contribution to journalArticle

Irie, Haruko ; Banno, Kouji ; Yanokura, Megumi ; Iida, Miho ; Adachi, Masataka ; Nakamura, Kanako ; Umene, Kiyoko ; Nogami, Yuya ; Masuda, Kenta ; Kobayashi, Yusuke ; Tominaga, Eiichiro ; Aoki, Daisuke. / Metformin : A candidate for the treatment of gynecological tumors based on drug repositioning (Review). In: Oncology Letters. 2016 ; Vol. 11, No. 2. pp. 1287-1293.
@article{08f98b78c91e405db2ea2b0d073ccba1,
title = "Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning (Review)",
abstract = "Metformin is a first-line drug used for the treatment of type 2 diabetes. Recently, metformin has been reported to reduce the carcinogenic risk and inhibit tumor cell growth in glioma and breast cancer. The anticancer action of metformin involves the enhancement of phosphorylation of liver kinase B1, activation of adenosine monophosphate-activated protein kinase and inhibition of mammalian target of rapamycin, which reduces cell growth. Metformin is anticipated to exert antitumor effects in gynecological cancer, and its efficacy for the treatment of endometrial, breast and ovarian cancer has been suggested in preclinical studies and clinical trials. Although the effect of metformin on cervical cancer remains to be examined in clinical trials, its antitumor effects have been reported in preclinical studies. Thus, the use of metformin for the treatment of gynecological cancer may become a successful example of drug repositioning, following establishment of the drug's antitumor effects, risk evaluation, screening and validation of efficacy.",
keywords = "Breast cancer, Drug repositioning, Endometrial cancer, Metformin, Ovarian cancer",
author = "Haruko Irie and Kouji Banno and Megumi Yanokura and Miho Iida and Masataka Adachi and Kanako Nakamura and Kiyoko Umene and Yuya Nogami and Kenta Masuda and Yusuke Kobayashi and Eiichiro Tominaga and Daisuke Aoki",
year = "2016",
month = "2",
day = "1",
doi = "10.3892/ol.2016.4075",
language = "English",
volume = "11",
pages = "1287--1293",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Metformin

T2 - A candidate for the treatment of gynecological tumors based on drug repositioning (Review)

AU - Irie, Haruko

AU - Banno, Kouji

AU - Yanokura, Megumi

AU - Iida, Miho

AU - Adachi, Masataka

AU - Nakamura, Kanako

AU - Umene, Kiyoko

AU - Nogami, Yuya

AU - Masuda, Kenta

AU - Kobayashi, Yusuke

AU - Tominaga, Eiichiro

AU - Aoki, Daisuke

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Metformin is a first-line drug used for the treatment of type 2 diabetes. Recently, metformin has been reported to reduce the carcinogenic risk and inhibit tumor cell growth in glioma and breast cancer. The anticancer action of metformin involves the enhancement of phosphorylation of liver kinase B1, activation of adenosine monophosphate-activated protein kinase and inhibition of mammalian target of rapamycin, which reduces cell growth. Metformin is anticipated to exert antitumor effects in gynecological cancer, and its efficacy for the treatment of endometrial, breast and ovarian cancer has been suggested in preclinical studies and clinical trials. Although the effect of metformin on cervical cancer remains to be examined in clinical trials, its antitumor effects have been reported in preclinical studies. Thus, the use of metformin for the treatment of gynecological cancer may become a successful example of drug repositioning, following establishment of the drug's antitumor effects, risk evaluation, screening and validation of efficacy.

AB - Metformin is a first-line drug used for the treatment of type 2 diabetes. Recently, metformin has been reported to reduce the carcinogenic risk and inhibit tumor cell growth in glioma and breast cancer. The anticancer action of metformin involves the enhancement of phosphorylation of liver kinase B1, activation of adenosine monophosphate-activated protein kinase and inhibition of mammalian target of rapamycin, which reduces cell growth. Metformin is anticipated to exert antitumor effects in gynecological cancer, and its efficacy for the treatment of endometrial, breast and ovarian cancer has been suggested in preclinical studies and clinical trials. Although the effect of metformin on cervical cancer remains to be examined in clinical trials, its antitumor effects have been reported in preclinical studies. Thus, the use of metformin for the treatment of gynecological cancer may become a successful example of drug repositioning, following establishment of the drug's antitumor effects, risk evaluation, screening and validation of efficacy.

KW - Breast cancer

KW - Drug repositioning

KW - Endometrial cancer

KW - Metformin

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84954350249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954350249&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.4075

DO - 10.3892/ol.2016.4075

M3 - Article

AN - SCOPUS:84954350249

VL - 11

SP - 1287

EP - 1293

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -